Search clinical trials for: Camrelizumab; apatinib

Total 549 results

Di Wu

Recruiting

Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

Acral Melanoma

China
West China Hospital

Recruiting

Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma

Adrenocortical Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

China
Hebei Medical University Fourth Hospital

Recruiting

Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor

Advanced Solid Tumor

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

Recurrent Glioma

China
Chinese PLA General Hospital

Recruiting

The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer

BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification (TRIPLET)

C-staged Hepatocellular Carcinoma in BCLC Classification

China
Zhejiang Cancer Hospital

Recruiting

Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study

Gastric Adenocarcinoma

China
University of Copenhagen
Copenhagen University Hospital, Hvidovre

Recruiting

Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.

Obesity

Denmark
Azienda Sanitaria-Universitaria Integrata di Udine

Recruiting

Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC) (TANDEM)

Subarachnoid Hemorrhage | Therapeutic Drug Monitoring | Intracerebral Hemorrhage

Italy
Fujian Cancer Hospital

Not yet recruiting

Study of the Apatinib Combine With POF Versus POF in Gastric Cancer

Gastric Adenocarcinoma | Advanced Cancer

China
HRYZ Biotech Co.

Recruiting

MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma

Sarcoma

China
Ruijin Hospital

Recruiting

BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (BIOVAS)

Sarcoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma

Soft Tissue Sarcoma

China
China Medical University, China

Recruiting

PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

Gastric Cancer | AFP

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

Triple-negative Breast Cancer
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC

Locally Advanced Esophageal Squamous Cell Carcinoma

China
Fudan University

Not yet recruiting

The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer

Neoplasms | Stomach Neoplasms | Gastrointestinal Neoplasms | Digestive System Neoplasms | Stomach Diseases | Molecular Mechanisms of Pharmacological Action | Capecitabine | Apatinib
Qilu Hospital of Shandong University

Recruiting

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Gastric Cancer

China
Hebei Medical University Fourth Hospital

Not yet recruiting

A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection

Hepatocellular Carcinoma

China
Fudan University

Recruiting

FUSCC Refractory TNBC Umbrella (FUTURE) (FUTURE)

Triple-negative Breast Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Esophageal Cancer

China
Sun Yat-sen University
Southern Medical University, China; Shantou University Medical College; Guangzhou...

Recruiting

Randomized Study of Adjuvant Radiotherapy After Curative Resection of HCC With Narrow Margin (RAISE) (RAISE)

Hepatocellular Carcinoma | Hepatectomy | Radiotherapy

China
Anhui Provincial Hospital

Not yet recruiting

XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma

Gastric Carcinoma

China
The First Affiliated Hospital of Xiamen University

Not yet recruiting

Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial

Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety

China
Hebei Medical University

Not yet recruiting

A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Gastric Cancer
Tianjin Medical University Cancer Institute and...

Not yet recruiting

XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma

Gastric Carcinoma
Third Military Medical University

Not yet recruiting

Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin

Small Cell Lung Cancer
Sun Yat-sen University

Recruiting

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors

China
Elevar Therapeutics

Terminated

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Adenoid Cystic Carcinoma

United States, Korea, Republic of
Peking University People's Hospital
Peking University Shougang Hospital

Suspended

Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma (AIEO)

Effect of Drug | Toxicity, Drug

China
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) (OAIE)

Toxicity | Effect of Drug | Drug

China
University of California, San Francisco
Gilead Sciences; ViiV Healthcare

Active, not recruiting

Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection (DGVTAF)

HIV

United States
Elevar Therapeutics

Terminated

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

United States
RenJi Hospital

Active, not recruiting

Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer (APP)

Breast Cancer

China
Fujian Medical University

Completed

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.

Neoadjuvant Therapy | Advanced Gastric Cancer | Multi-omics Analysis

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Sarcoma

China
Xinqiao Hospital of Chongqing

Withdrawn

Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients (XQonc-007)

Advanced Non-squamous Non-small-cell Lung Cancer

China
Xinqiao Hospital of Chongqing

Withdrawn

Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen

Advanced Non-squamous Non-small-cell Lung Cancer

China
AbbVie

Enrolling by invitation

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR (Maia)

Ocular Hypertension | Open-Angle Glaucoma

United States, Argentina, Belgium, Brazil, Canada, Colombia, Czechia, Denmark, Egypt, France, Germany, Hong Kong, Italy, Korea, Republic of, New Zealand, Peru, Philippines, Poland, Russian Federation, Singapore, South Africa, Spain, Thailan... and more
AbbVie

Active, not recruiting

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States, Argentina, Australia, Bulgaria, Czechia, Denmark, Germany, Hungary, Ireland, Italy, New Zealand, Poland, Russian Federation, South Africa, Sweden, United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Locally Advanced or Metastatic and Unresectable HCC

United States, Spain, China, Taiwan, Belgium, Korea, Republic of, Italy, Hong Kong, Russian Federation, Ukraine, Turkey, Poland, Germany
Renmin Hospital of Wuhan University

Completed

First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC (RENMIN-213)

Advanced Gastric Adenocarcinoma

China
Beijing Friendship Hospital

Completed

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Biliary Tract Cancer | Capecitabine | Targeted Molecular Therapy | Anti-PD-1 Therapy

China
Jiangsu HengRui Medicine Co., Ltd.
NanJing PLA 81 Hospital

Completed

Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

Carcinoma, Hepatocellular

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Gastric Cancer | GastroEsophageal Cancer

China
Wuhan Union Hospital, China

Withdrawn

Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer (XHZL)

Colorectal Cancer | Chemotherapy | Angiogenesis
Zhongda Hospital

Active, not recruiting

TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

Hepatocellular Carcinoma

China
University of Miami
Pfizer

Completed

Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

Ulcerative Colitis

United States

Search clinical trials for: Camrelizumab; apatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations